Waheed Adeola Adedeji1, Sharon Iyobor Igbinoba2, Titilayo O Fakeye3, Ibrahim Adebayo Oladosu4, Fatai Adewale Fehintola1,5, Qing Ma6, Gene D Morse6,7. 1. a Department of Clinical Pharmacology , University College Hospital , Ibadan , Nigeria. 2. b Department of Clinical Pharmacy & Pharmacy Administration, Faculty of Pharmacy , Obafemi Awolowo University , Ile-Ife , Nigeria. 3. c Department of Clinical Pharmacy & Pharmacy Administration , University of Ibadan , Ibadan , Nigeria. 4. d Department of Chemistry , University of Ibadan , Ibadan , Nigeria. 5. e Department of Pharmacology and Therapeutics , University of Ibadan , Ibadan , Nigeria. 6. f Translational Pharmacology Research Core , School of Pharmacy and Pharmaceutical Sciences, New York Center of Excellence in Bioinformatics and Life Sciences , Buffalo , NY , USA. 7. g Center for Integrated Global Biomedical Sciences , University at Buffalo , Buffalo , NY , USA.
Abstract
BACKGROUND: There is a lack of information on CYP2D6, a major metabolizing enzyme, in Africa ethnic nationalities. The objective was to determine CYP2D6 phenotype in Yoruba Nigerians using dextromethorphan (DEX). METHOD: A total of 89 healthy volunteers received 30 mg of DEX orally followed by blood and urine sample collection at 3-hour and over 8 h post-dose, respectively. DEX and dextrorphan (DOR) concentrations were determined using High Performance Liquid Chromatography (HPLC). The metabolic ratio (MR, DEX/DOR) were plotted for the phenotype determination. RESULTS: The log MR that separated poor (PMs) from normal metabolizers (NMs) was 0.28 and 0.75 for urine and plasma, respectively. Two subjects (2.3%) identified as PMs had a mean MR of 17 and 3.2 in plasma and urine, significantly higher than that of NMs (p < .0001). A positive correlation between urine and plasma MR was noted. CONCLUSION: The prevalence of PMs in the Yoruba Nigerians was similar to that reported among blacks.
BACKGROUND: There is a lack of information on CYP2D6, a major metabolizing enzyme, in Africa ethnic nationalities. The objective was to determine CYP2D6 phenotype in Yoruba Nigerians using dextromethorphan (DEX). METHOD: A total of 89 healthy volunteers received 30 mg of DEX orally followed by blood and urine sample collection at 3-hour and over 8 h post-dose, respectively. DEX and dextrorphan (DOR) concentrations were determined using High Performance Liquid Chromatography (HPLC). The metabolic ratio (MR, DEX/DOR) were plotted for the phenotype determination. RESULTS: The log MR that separated poor (PMs) from normal metabolizers (NMs) was 0.28 and 0.75 for urine and plasma, respectively. Two subjects (2.3%) identified asPMs had a mean MR of 17 and 3.2 in plasma and urine, significantly higher than that of NMs (p < .0001). A positive correlation between urine and plasma MR was noted. CONCLUSION: The prevalence of PMs in the Yoruba Nigerians was similar to that reported among blacks.
Authors: E Aklillu; I Persson; L Bertilsson; I Johansson; F Rodrigues; M Ingelman-Sundberg Journal: J Pharmacol Exp Ther Date: 1996-07 Impact factor: 4.030
Authors: C Dandara; C M Masimirembwa; A Magimba; J Sayi; S Kaaya; D K Sommers; J R Snyman; J A Hasler Journal: Eur J Clin Pharmacol Date: 2001-04 Impact factor: 2.953
Authors: Issam Zineh; Amber L Beitelshees; Andrea Gaedigk; Joseph R Walker; Daniel F Pauly; Kathleen Eberst; J Steven Leeder; Michael S Phillips; Craig A Gelfand; Julie A Johnson Journal: Clin Pharmacol Ther Date: 2004-12 Impact factor: 6.875